Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3Phase 3 1Phase 1/2 1

Status

Recruiting 17Active not recruiting 8Not yet recruiting 2Completed 2

Sponsor Class

INDUSTRY 7OTHER 1

Study Type

Interventional 8

Sponsor

Cancer Type

Plasma cell 7Other hematologic neoplasm 1

Conditions

Multiple Myeloma 7Recurrence 1Hematologic Neoplasms 1

Interventions

pembrolizumab 436Carboplatin 321Nivolumab 287Cyclophosphamide 280Specimen Handling 257Cisplatin 251Paclitaxel 248Magnetic Resonance Spectroscopy 248Radiotherapy 217Gemcitabine 180Dexamethasone 180Biopsy 177durvalumab 166atezolizumab 148Rituximab 138Lenalidomide 134Doxorubicin 134Docetaxel 130Bevacizumab 129Ipilimumab 125Radiation 118Capecitabine 117Pemetrexed 112Oxaliplatin 112Etoposide 111Radiosurgery 108Fluorouracil 108venetoclax 106fludarabine 106Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

8 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × talquetamab × Clear all
NCT03399799 2026-06-05

MonumenTAL-1

Janssen Research & Development, LLC

Phase 1 Active not recruiting
279 enrolled 1 FDA
Other hematologic neoplasm

Hematologic Neoplasms

NCT04108195 2026-06-05

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

Janssen Research & Development, LLC

Phase 1 Active not recruiting
290 enrolled
Plasma cell

Multiple Myeloma

NCT05050097 2026-06-05

MonumenTAL-2

Janssen Research & Development, LLC

Phase 1 Active not recruiting
166 enrolled
Plasma cell

Multiple Myeloma

NCT06550895 2026-06-05

MonumenTAL-8

Janssen Research & Development, LLC

Phase 2 Active not recruiting
11 enrolled
Plasma cell

Multiple Myeloma

NCT06577025 2026-06-05

aMMbition

Janssen Research & Development, LLC

Phase 2 Active not recruiting
43 enrolled
Plasma cell

Multiple Myeloma

NCT05455320 2026-04-13

MonumenTAL-3

Janssen Research & Development, LLC

Phase 3 Active not recruiting
864 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT06353022 2026-03-17

IFm2022-01

Nantes University Hospital

Phase 2 Active not recruiting
103 enrolled
Plasma cell

Multiple Myeloma

NCT04586426 2026-01-16

RedirecTT-1

Janssen Research & Development, LLC

Phase 1/2 Active not recruiting
228 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡